Gross Profit for Vertex Pharmaceuticals (VRTX)
According to Vertex Pharmaceuticals's latest reported financial statements, the company's current gross profit (TTM) is $10.39B USD. Gross profit equals revenue minus the cost of goods sold (COGS) — what remains from sales after the direct cost of producing the product or service. It does not yet subtract operating expenses, interest, or taxes (see operating income and net income for those steps). Higher gross profit (and gross margin) generally signals pricing power and production efficiency.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
Currently viewingGross ProfitSwitch metric
TTM (last 4 quarters)
$10.39B
YoY change
+8.2%
5Y CAGR
+13.4%
Peak year (2025)
$10.27B
Cumulative gross profit
$65.09B
Gross Profit history chart for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
Gross Profit history table for Vertex Pharmaceuticals (VRTX) from 1990 to 2025
| Fiscal year | Period ended | Reported | Gross Profit | YoY |
|---|---|---|---|---|
| 2025 | $10.27B | +8.2% | ||
| 2024 | $9.49B | +10.3% | ||
| 2023 | $8.61B | +9.6% | ||
| 2022 | $7.85B | +17.7% | ||
| 2021 | $6.67B | +22.0% | ||
| 2020 | $5.47B | +51.3% | ||
| 2019 | $3.62B | +37.0% | ||
| 2018 | $2.64B | +19.2% | ||
| 2017 | $2.21B | +48.4% | ||
| 2016 | $1.49B | +64.5% | ||
| 2015 | $906.79M | +74.6% | ||
| 2014 | $519.43M | -52.0% | ||
| 2013 | $1.08B | -13.3% | ||
| 2012 | $1.25B | -6.2% | ||
| 2011 | $1.33B | +918.2% | ||
| 2010 | $130.64M | +48.7% | ||
| 2009 | $87.85M | -45.0% | ||
| 2008 | $159.82M | -13.7% | ||
| 2007 | $185.11M | -9.3% | ||
| 2006 | $204.19M | +35.4% | ||
| 2005 | $150.79M | +55.3% | ||
| 2004 | $97.07M | +47.0% | ||
| 2003 | $66.02M | -50.3% | ||
| 2002 | $132.80M | +3.9% | ||
| 2001 | $127.86M | +72.7% | ||
| 2000 | $74.05M | +13.9% | ||
| 1999 | $65.00M | +32.9% | ||
| 1998 | $48.90M | +3.2% | ||
| 1997 | $47.40M | +187.3% | ||
| 1996 | $16.50M | -36.0% | ||
| 1995 | $25.80M | +11.7% | ||
| 1994 | $23.10M | -27.4% | ||
| 1993 | $31.80M | +381.8% | ||
| 1992 | $6.60M | +32.0% | ||
| 1991 | $5.00M | +117.4% | ||
| 1990 | $2.30M | — |
Gross Profit values are taken from Vertex Pharmaceuticals's reported income statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Vertex Pharmaceuticals (VRTX) reported gross profit of $10.27B – grew 8.2% year-over-year.
Vertex Pharmaceuticals gross profit compound annual growth for the 2020–2025 (5 years) window is +13.4%, sustaining 11 straight years of year-over-year growth.
2025 marks the peak gross profit at $10.27B, with the historical low of $2.30M recorded in 1990.
Within Healthcare, Vertex Pharmaceuticals (VRTX) ranks 9th among 8 peers we track. The peer median for gross profit is $53.80B.
Vertex Pharmaceuticals Gross Profit by Year
Vertex Pharmaceuticals Gross Profit 2025: $10.27B
Vertex Pharmaceuticals gross profit in 2025 was $10.27B, grew 8.2% from 2024. This figure represents the highest annual value in the available history.
Vertex Pharmaceuticals Gross Profit 2024: $9.49B
Vertex Pharmaceuticals gross profit in 2024 was $9.49B, grew 10.3% from 2023.
Vertex Pharmaceuticals Gross Profit 2023: $8.61B
Vertex Pharmaceuticals gross profit in 2023 was $8.61B, grew 9.6% from 2022.
Vertex Pharmaceuticals Gross Profit 2022: $7.85B
Vertex Pharmaceuticals gross profit in 2022 was $7.85B, grew 17.7% from 2021.
Vertex Pharmaceuticals Gross Profit 2021: $6.67B
Vertex Pharmaceuticals gross profit in 2021 was $6.67B.
See more financial history for Vertex Pharmaceuticals (VRTX).
Sector peers — Gross Profit
Companies in the same sector as Vertex Pharmaceuticals, ranked by their latest gross profit.
| Company | Gross Profit | Sector |
|---|---|---|
| Novo Nordisk A/S (NVO) | $250.28B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $82.92B | Healthcare |
| Johnson & Johnson (JNJ) | $68.56B | Healthcare |
| Eli Lilly and Company (LLY) | $54.62B | Healthcare |
| Merck & Co., Inc. (MRK) | $52.98B | Healthcare |
| AstraZeneca PLC (AZN) | $48.11B | Healthcare |
| AbbVie Inc. (ABBV) | $42.96B | Healthcare |
| Amgen Inc. (AMGN) | $26.01B | Healthcare |
Frequently asked questions
What is Vertex Pharmaceuticals's gross profit?
- Latest reported gross profit for Vertex Pharmaceuticals (VRTX) is $10.39B (period ending December 31, 2025).
How has Vertex Pharmaceuticals gross profit changed year-over-year?
- Vertex Pharmaceuticals (VRTX) gross profit changed +8.2% year-over-year on the latest annual filing.
What is the long-term growth rate of Vertex Pharmaceuticals gross profit?
- Vertex Pharmaceuticals (VRTX) gross profit compound annual growth rate is +13.4% over the most recent 5 years available.
When did Vertex Pharmaceuticals gross profit hit its highest annual value?
- Vertex Pharmaceuticals gross profit reached its highest annual value of $10.27B in 2025.
What was Vertex Pharmaceuticals gross profit in 2024?
- Vertex Pharmaceuticals (VRTX) gross profit in 2024 was $9.49B.
What was Vertex Pharmaceuticals gross profit in 2025?
- Vertex Pharmaceuticals (VRTX) gross profit in 2025 was $10.27B.
Metrics overview
Pick a metric for charts, filings, and peers — each row shows the latest TTM or annual value with year-over-year change.
Explore more
VRTX Overview
Company profile, financial tools, and key metrics
VRTX Revenue Counter
Earns $381.74 every second. See per minute, hour, and day.
VRTX Earnings Counter
Earns $125.36 per second net profit. See per minute, hour, and day.
VRTX Economic Scale
Exceeds Somalia, Fed. Rep.'s GDP. Compare with world economies.
VRTX What If Invested
What if you had invested $1,000? See historical returns from any date.
VRTX How It Makes Money
Discover visual breakdown of $12.04B in revenue — where it comes from and where it goes.
VRTX Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
VRTX Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
VRTX Daily Price Character
Explosive · 48.3% historical win rate (green days). Streaks & record days.
VRTX Buybacks
1.75% TTM buyback yield. Shareholder yield & SBC comparison.
VRTX Stock Split History
1 split on record. Dates, ratios, and cumulative multiple.